Skip to content
Search

Latest Stories

UCL proposes simple daily pill that prevents heart attacks and strokes

Moving from treatment to prevention on a grand scale.

daily pill

This new approach could make life-saving medication accessible to millions

iStock

Imagine a single daily pill that could dramatically cut your risk of heart attacks and strokes. Sounds almost too good to be true, right? Well, scientists from University College London (UCL) believe this vision could soon be a reality. The breakthrough "polypill" combines a statin and three blood pressure-lowering medications, promising to transform how we prevent cardiovascular diseases, one of the UK’s biggest health challenges.

A revolutionary approach to heart disease prevention


Heart disease and strokes are silent killers, claiming thousands of lives each year. The current NHS Health Check programme helps identify at-risk individuals, but the system isn’t reaching nearly enough people. Fewer than half of those eligible even attend their appointments. This means that countless lives could be saved if more people were offered preventive treatment.

That’s where the polypill comes in. Rather than relying on complex risk assessments, UCL experts suggest a much simpler approach: offering the polypill to everyone aged 50 and over. No lengthy health checks, just the pill. This could make it a revolutionary tool in preventing heart attacks and strokes on a massive scale.

What exactly is the polypill?

The polypill is a combination of four well-established drugs: a statin to lower cholesterol and three different blood pressure-lowering medications. The idea of combining these drugs isn’t new; it dates back to a 2003 study that suggested a polypill could prevent up to 80% of heart attacks and strokes in people over 55. Since then, various trials have backed up these claims.

Professor Aroon Hingorani, a leading UCL researcher, explains that most heart attacks and strokes happen in people with “average” risk levels, which means the current system of identifying high-risk individuals often misses the mark. Offering the polypill to everyone over 50 could potentially save far more lives.

A simple, life-saving solution

One of the biggest advantages of the polypill is its simplicity. There’s no need for complicated medical assessments, just a few basic questions to check for side effects. Once that’s done, eligible people can start taking the pill, drastically reducing their risk of heart-related problems.

UCL researchers estimate that even if only 8% of people over 50 take up the offer, the health benefits would far exceed what’s currently achieved through the NHS Health Check. This new approach could make life-saving medication accessible to millions in the same way that vaccines or folic acid fortification do.

Professor Sir Nicholas Wald, another UCL co-author, compares the polypill approach to other public health programmes designed to prevent illness before it happens. “This isn’t about medicalising half the population,” Wald points out. “It’s about making sure people don’t become patients in the first place.”

Affordable, proven, and effective

The polypill is not only effective but also affordable. The medications it contains are all off-patent, meaning they’re inexpensive to produce. Despite the low cost, these drugs have a long-standing track record of success with minimal side effects. In particular, combining three blood pressure drugs at low doses reduces the risk of side effects even further while maximising the benefits.

In 2019, a landmark study in rural Iran showed that taking the polypill for five years reduced heart attacks and strokes by a third. This dramatic finding demonstrates the real-world potential of the polypill to change the game not just in the UK but globally.

What’s next for the polypill?

With such compelling evidence, the next step is figuring out how to introduce the polypill programme nationwide. UCL researchers have proposed a pilot project to evaluate how best to roll it out, looking at factors such as cost, uptake, and long-term effectiveness.

However, for this plan to become a reality, it would require policy changes. Currently, local authorities are required to offer NHS Health Checks, and a polypill programme would need to replace or supplement this. But the UCL team is confident this shift is necessary, calling the current situation “untenable.”

With over seven million people in the UK affected by cardiovascular disease, and more than 200,000 heart attacks and strokes every year, it’s clear that a new approach is desperately needed. The polypill could be that solution: a simple, affordable, and effective way to prevent countless deaths and reduce the burden on the NHS.

A new era in prevention

The polypill isn’t just another medical treatment; it could be the key to unlocking a future with fewer heart attacks and strokes. By offering this life-saving pill to everyone over 50, we could see a drastic reduction in cardiovascular diseases. The scientific evidence is strong, the potential impact is huge, and the time to act is now.

As we wait for further studies and potential rollouts, one thing is certain: prevention is always better than cure, and the polypill could very well be the future of heart disease prevention.

More For You

Sue Perkins

Sue Perkins has previously been praised for her openness about personal challenges

Getty

Comedian Sue Perkins says ADHD is not an 'excuse' to avoid responsibility

Television presenter and comedian Sue Perkins has spoken candidly about her experience of living with attention deficit hyperactivity disorder (ADHD), emphasising that she does not "weaponise" her diagnosis to excuse her behaviour.

Perkins, 55, is well known for her role as a former co-host of The Great British Bake Off, as well as for her current work on the BBC game show Chess Masters: Endgame. Speaking in an interview with Radio Times, she reflected on her relatively recent diagnosis of ADHD and the impact it has had on her understanding of herself.

Keep ReadingShow less
Coeliac Disease: What to Know After Rebecca Adlington’s Diagnosis

Olympic swimmer Rebecca Adlington has recently revealed about her condition

Getty Images

Key things to know about Coeliac disease after Rebecca Adlington’s diagnosis

Olympic swimmer Rebecca Adlington has recently revealed her diagnosis of coeliac disease and has called for greater awareness of the condition. In a video shared on Coeliac UK’s Instagram, Adlington discussed the importance of gluten-free prescriptions and urged the government to protect access to these prescriptions, which have been cut in some areas.

Her diagnosis shines a light on coeliac disease, a condition that affects approximately 1 in 100 people in the UK. However, due to the difficulty in recognising the symptoms, only around 36% of people living with the condition have been officially diagnosed.

Keep ReadingShow less
Coca-Cola Issues Recall for 900 Cases Due to Plastic Contamination

The recall is classified as a Class II event by the FDA

iStock

Coca-Cola recalls nearly 900 cases due to plastic contamination

Reyes Coca-Cola Bottling, LLC, based in Milwaukee, Wisconsin, has initiated a recall of nearly 900 cases of Coca-Cola Original Taste due to potential contamination with plastic. The recall affects 864 12-pack cases of Coca-Cola, which were distributed to retailers in Illinois and Wisconsin. The recall was announced on 6th March 2025, and is currently still in progress, according to the Food and Drug Administration (FDA).

The recall is classified as a Class II event by the FDA, which means that while the risk of severe health consequences is considered low, consumers may still experience temporary or reversible adverse effects. Plastic contamination in beverages poses a number of risks, including the potential for choking, oral injuries, or gastrointestinal discomfort if consumed.

Keep ReadingShow less
Eli Lilly

This price point is significantly lower than in the USA

Getty Images

Eli Lilly introduces Mounjaro in India, gaining an edge over Novo Nordisk in the weight-loss drug market


Eli Lilly has launched its highly anticipated diabetes and weight-loss medication, Mounjaro, in India, marking the company's entry into the country’s rapidly growing market for treatments tackling obesity and diabetes. The U.S.-based pharmaceutical giant has outpaced Danish competitor Novo Nordisk, becoming the first to offer such a drug in India.

Keep ReadingShow less
 Listeria

Health officials have launched an investigation to determine the full extent of the contamination

Getty Images

3 dead, 5 seriously ill due to listeria after eating chocolate dessert

Three people have died and five others have fallen seriously ill following a listeria outbreak linked to a chocolate dessert supplied to NHS hospitals across the UK. Health officials have launched an investigation to determine the full extent of the contamination, which has prompted a nationwide recall of chilled desserts from hospitals and care homes.

The Food Standards Agency (FSA) has identified mousses and ice creams made by Cool Delight Desserts as the suspected source of the listeria outbreak. This recall covers all chilled desserts including mousses, ice creams, ice cream rolls, and yoghurts supplied by the company to NHS facilities. The action is being taken as a precaution while health authorities continue their investigation.

Keep ReadingShow less